Australian Clinical Labs logs $$35.5M FY26 net profit
- The company recorded a 4.3% increase in underlying net profit to $35.5 million.
- Operating margins expanded slightly despite a 0.7% decline in total revenue to $735.8 million.
- Management attributed the result to procurement savings and expects improved market growth moving forward.
Australian Clinical Labs (ASX:ACL) reported an underlying net profit of $35.5 million for the 2026 financial year, representing a 4.3% increase compared to the previous reporting period.
Underlying EBIT climbed up to $69.2 million, while EPS inched up to 18.3 cents per share.
“Amid subdued GP attendance volumes, Medicare fee changes and persistent inflationary pressure, we maintained a clear focus on our strategy, improving margins year on year to 9.4%,” said Australian Clinical Labs CEO Melinda McGrath.
The company stated that it expects revenue between $745 million and $765 million for the 2027 financial year.
The company’s board declared a final fully franked dividend of 9.25 cents per share.
Looking towards selective expansion opportunities, following the announcement, the Australian Clinical Labs share price was unchanged at $2.66.
The business relies on a strategy of offsetting wage cost increases through automation and digital transformation.
The healthcare provider generates nearly 20% of its revenue from commercial contracts and genetics.
